CN106235311A - A kind of compositions promoting skeletal system health and application thereof - Google Patents
A kind of compositions promoting skeletal system health and application thereof Download PDFInfo
- Publication number
- CN106235311A CN106235311A CN201610613602.3A CN201610613602A CN106235311A CN 106235311 A CN106235311 A CN 106235311A CN 201610613602 A CN201610613602 A CN 201610613602A CN 106235311 A CN106235311 A CN 106235311A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- bone
- compositions
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000036541 health Effects 0.000 title claims abstract description 18
- 230000001737 promoting effect Effects 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 73
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 63
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 29
- 102000008186 Collagen Human genes 0.000 claims abstract description 28
- 108010035532 Collagen Proteins 0.000 claims abstract description 28
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 24
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 24
- 230000037182 bone density Effects 0.000 claims abstract description 23
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 21
- 229940071162 caseinate Drugs 0.000 claims abstract description 21
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 20
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 20
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 20
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 17
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 10
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 235000013601 eggs Nutrition 0.000 claims description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 4
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002061 ergocalciferol Drugs 0.000 claims description 3
- 235000001892 vitamin D2 Nutrition 0.000 claims description 3
- 239000011653 vitamin D2 Substances 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000014103 egg white Nutrition 0.000 claims description 2
- 210000000969 egg white Anatomy 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 208000001132 Osteoporosis Diseases 0.000 abstract description 9
- 206010003246 arthritis Diseases 0.000 abstract description 5
- 208000008822 Ankylosis Diseases 0.000 abstract description 4
- 208000006820 Arthralgia Diseases 0.000 abstract description 4
- 206010023198 Joint ankylosis Diseases 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 206010005963 Bone formation increased Diseases 0.000 abstract description 3
- 230000000192 social effect Effects 0.000 abstract description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 63
- 229910052791 calcium Inorganic materials 0.000 description 63
- 239000011575 calcium Substances 0.000 description 63
- 235000001465 calcium Nutrition 0.000 description 63
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000002356 skeleton Anatomy 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- 229940091250 magnesium supplement Drugs 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 230000037180 bone health Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 108010048734 sclerotin Proteins 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000019143 vitamin K2 Nutrition 0.000 description 2
- 239000011728 vitamin K2 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- QNTKVQQLMHZOKP-NEJDVEAASA-N (2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]- Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QNTKVQQLMHZOKP-NEJDVEAASA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001510 arthropathic effect Effects 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- QNTKVQQLMHZOKP-UHFFFAOYSA-N fructofuranosylnystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OCC3(OC4C(C(O)C(O)C(CO)O4)O)C(C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 QNTKVQQLMHZOKP-UHFFFAOYSA-N 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001089 mineralizing effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000021134 protein-rich food Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to field of health care food, particularly to a kind of compositions and application thereof having and promoting that skeletal system is healthy.Compositions of the present invention includes skimmed milk powder, oligofructose, Os Bovis grunniens, orangeade fruit powder, D glucosamine hydrochloride, bone collagen, chondroitin sulfate, Herba Epimedii extract, Rhizoma Drynariae extract, mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6, to to sufferers of osteoporosis face, and the crowd of the skeletal system obstacle such as ankylosis, arthritis, hyperosteogeny, arthralgia cramp has significant preventive and therapeutic effect, bone density can be increased, play the effect promoting that skeletal system is healthy.Compositions of the present invention may be used for preparation and promotes the health food of skeletal system health, has wide range of applications, has good economy and social effect.
Description
Technical field
The invention belongs to field of health care food, particularly to a kind of promote skeletal system healthy compositions and should
With.
Background technology
Bone health refers to the health of whole skeletal system, including bone, cartilage, joint, tendon, ligament etc..And mend merely
Calcium poor effect, does not ensures that the harmony of the pliability of whole skeletal system, motility, shock resistance, tension stress and entirety.
Therefore, for middle-aged and elderly people, supplement skeleton nutrition the most comprehensively, make the nutritional labeling in skeleton be equalized proportioning, just can make
Whole body is strong, pliable and tough and flexible.Nutrition required for bone health, mainly comprises collagen protein, calcium, vitamin D, ammonia
Base glucose etc..
Human body component has about 16% to be protein, and has the collagen protein of 30%～40% in protein.Collagen egg
White presented in insoluble fiber, there is height tensile energy, be to determine skeleton, cartilage, tendon, ligament and skin angle
Matter, blood vessel etc. organizes suppleness and the important component of elastic strength.In skeleton Organic substance, collagen protein accounts for 90%, and health is inhaled
The calcium received must be attached on collagen protein, its is possible to be deposited in a large number in skeleton.Meanwhile, collagen protein is also present in joint
In, decide the lubricity in joint, shock resistance；It is present in cartilage, makes cartilage high resilience, reduce friction；It is present in substrate
In Ceng so that it is there is good morphotropism and Compartmentalization.Calcium is the important component of skeleton, is mainly derived from food.But old people
Digestive and absorptive functions degenerate, be difficult to take in from food enough calcareous, so needing supplement calcium extraly.Mend simply
Fill calcareous little for calcium deficiency and osteoporotic help, and can not arrange external formation and endanger.A lot of old peoples are replenishing the calcium,
But always poor effect, this is because in health, collagen protein is not enough.Not having the collagen protein of abundance, the calcium in skeleton can run off
Faster, bone brittleness and loose easily fracture.Collagen protein, calcium are reasonably combined to be supplemented, and could protect bone health comprehensively.Dimension
Raw element D can promote that gastrointestinal tract, to the absorption of calcium in food, can make the calcium in blood shift in skeleton, can reduce kidney to calcium
Discharge, essential in preventing and treating osteoporosis.Not having vitamin D, human body just can not absorb and utilize calcium, China threpsology
The recommended intake that can advise people's vitamin D of more than 50 years old is 400 ius/sky.But the vitamin D of excess is to human body
Harmful, it should to take in accordance with the suggestion of doctor.D-glucosamine full name is glucosamine, and glucosamine, after human body converts, is formed
One of constituent of articular cartilage-proteoglycan, helps human body repairing articular cartilage.Proteoglycan is the important of articular cartilage
Constituent.Account for 31%, be resilient spherical, be filled in the network structure of collagen protein, be collectively forming articular cartilage.This dermoskeleton
Matter is loose in addition to the nutrient by supplementary necessity, also wants reasonable arrangement dietary structure, eats some phosphorous, vitamin more
And protein rich food.And strengthen physical training, the life style kept fit.
The big data accumulated over 5 years show, in participating in the crowd that bone is surveyed, people's skeletal health of 49% causes anxiety, this
Mean that the people of nearly half has osteoporosis problem or there is hidden danger.Additionally ankylosis, arthritis, hyperosteogeny, arthritis
The symptom crowd such as cramp bitterly is the most.Market of replenishing the calcium is then to start to walk relatively early in health products trade, a more traditional market.Warp
After advertisement marketing for many years and popularization, idea of replenishing the calcium is rooted in the hearts of the people.Calcium supplementing product market Annual sales volume once reached more than 100 hundred million
Unit.Whole people's calcium deficiency, the whole people replenish the calcium, and allow calcium product become extremely industry and pay close attention to important category.But systemic comprehensive skeleton is protected
Strong product is the most few.
Application No. CN200710018146, invention entitled " a kind of health food increasing bone density " disclosed health care
Food contains the raw material of following weight portion: Herba Epimedii 800-1200 part, Rhizoma Drynariae 400-600 part, Radix Angelicae Sinensis 200-300 part, Margarita
Powder 100-200 part, Colla Corii Asini bead 100-200 part, soybean isoflavone 50-100 part, vitamin D3 0.1-1 part, starch 120-160
Part.And Application No. CN201310088455.9, invention entitled " a kind of Health-protection traditional Chinese medicinal preparation increasing bone density and preparation thereof
Method " the disclosed Health-protection traditional Chinese medicinal preparation increasing bone density includes following weight component: Os Bovis seu Bubali powder 180-310 part, Herba Epimedii
330-460 part, Herba cuscutae 240-340 part, Fructus Ligustri Lucidi 200-300 part, Fructus Lycii 500-700 part, Radix Ginseng 180-260 part, hydrochloric acid ammonia
Base glucose 70-120 part.But above-mentioned prescription all lacks the osteoarticular component of protection.Application No. CN201310030954,
Disclosed in invention entitled " a kind of compositions with increase bone substance density improving function and its production and use ", there is increase bone
The compositions of density function, it is made up of the raw material of following weight portion: D-Glucosamine Hydrochloride 10～30 parts, chondroitin sulfate
Element 8～15 parts, collagen protein 2～8 parts, Rhizoma Drynariae extract 1～7 parts, Herba Epimedii extract 1～7 parts, milk calcium 10～30 parts,
Vitamin D3 10-7～10-4 part, in wherein said milk calcium, the mass content of calcium is more than or equal to 25%, viscous in described collagen protein
The mass content of polysaccharide is more than or equal to 25%；Described Herba Epimedii extract is more than or equal to the Herba Epimedii of 10% containing mass fraction
Glycosides, Rhizoma Drynariae extract refers to the extract that Rhizoma Drynariae dry rhizome obtains through alcohol extraction.But this prescription lacks promotion calcium turn
The component that fortune absorbs.
Summary of the invention
In view of this, present invention aims to above-mentioned the deficiencies in the prior art, it is provided that a kind of promotion skeletal system
Healthy compositions and application thereof.The present composition to sufferers of osteoporosis face, and ankylosis, arthritis, hyperosteogeny,
The crowd of the skeletal system obstacles such as arthralgia cramp has significant preventive and therapeutic effect, can play the work promoting that skeletal system is healthy
With.
The invention provides a kind of compositions, be made up of following raw material: skimmed milk powder 0-230 part, oligofructose
0-200 part, yak bone powder 50-190 part, orangeade fruit powder 0-170 part, D-Glucosamine Hydrochloride 100-140 part, ossein
Albumen 0-100 part, chondroitin sulfate 65-95 part, Herba Epimedii extract 15-25 part, Rhizoma Drynariae extract 15-25 part, mushroom powder
4-9 part, magnesium carbonate 0.1-2.1 part, phosphopeptide caseinate 0.1-1.3 part, Menaquinone K6 0.1-0.9 part.
Oligofructose, also known as fructooligosaccharide, is by β (2-1) glycosidic bond and the fructose in sucrose by 1～3 fructosyl
The mixture of ketose, C24H42 O21 and Fructofuranosyl nystose etc. that base junction symphysis becomes.Oligofructose of the present invention is responsible at stomach
The calcium transport of middle complexation absorbs to release in large intestine, is referred to as " the long-distance transport protection instrument " of calcium.Oligofructose can not be by stomach
Digest and assimilate with small intestinal, it is possible to sequentially arrive large intestine, large intestine is fermented generation chain rupture fatty acid, oligomeric in large intestine
Fructose can help the human body absorption to elements such as mineral such as calcium, ferrum, magnesium, and it has the work of dietary fiber bind metal ion
With；" oligofructose-mineral complex " is formed, after once arriving large intestine, with oligofructose by bacillus bifidus etc. in gastrointestinal
Fermentable decomposes, and discharges mineral (such as calcium ion, magnesium ion etc.) the most simultaneously, and oligofructose is decomposed by bacillus bifidus etc.
Producing short-chain fatty acid and reduce the pH value of intestinal, in sour environment, the solubility of minerals such as calcium, magnesium increases, and its biology has
Effect property have also been obtained the biggest raising, and short-chain fatty acid (particularly butanoic acid) can also stimulate conjunctival cells to grow in addition, thus carries
The high intestinal mucosa absorbability to mineral.Secondly oligofructose can nurse one's health intestinal, alleviates indivedual crowd and causes just because replenishing the calcium
Secret.
Yak bone powder yak of the present invention is that the fresh bone by yak and bone marrow are through biological engineering and micronizing processing etc.
Out, pure taste, without any gritty sense, rich in proteins, several amino acids, chrondroitin and bone for new and high technology process for producing
Collagen, calcium, phosphorus ratio are 2:1, for pure natural organic calcium source, are easily absorbed by the body.
D-Glucosamine Hydrochloride described in compositions of the present invention is by natural chitin extraction, is a kind of
Marine biological preparation, can promote the synthesis of human body mucopolysaccharide, improves the viscosity of knuckle synovia, improves the metabolism of articular cartilage.
Bone collagen described in compositions of the present invention can form collagen fiber, osseomucoid, crosslinking curing calcium, keeps away
Exempt from calcium loss.
Chondroitin sulfate is the mucopolysaccharide class material being extracted from animal cartilage, in cardiovascular disease, arthropathic preventing and treating etc.
Aspect has important effect, and chondroitin sulfate is provided that pad effect, relaxes impact when taking action and friction；As conveying pipe
Road, chondroitin sulfate is that cartilage carries important oxygen confession and nutrient, carbon dioxide and refuse is got rid of simultaneously.Additionally sulfur
Aching and limp ossein may also suppress the ferment (such as collagenase, elastoser and cathepsin) destroying cartilage, in order to avoid cartilage quilt
Decompose or dissolve.
Herba Epimedii tool kidney-replenishing, bone and muscle strengthening, the effect of wind-damp dispelling, for impotence and seminal emission, soft, the rheumatic arthralgia of muscles and bones flaccidity etc.
Disease, Herba Epimedii extract described in compositions of the present invention is the extract that Herba Epimedii is dried stem and leaf, for phytoandrogen, energy
Increase cardiovascular and cerebrovascular vessel blood flow, promote hemopoietic function, improve immunologic function and bone metabolism also there is kidney invigorating and YANG supporting, anti-ageing wait for a long time
Effect, the most also has " Psoralen " effect, has good preventive and therapeutic effect to osteoporosis, to prolonged application adrenocortical hormone
Caused osteoporosis has antagonism, can by affecting osteoblastic proliferation, differentiation and mineralising promoting bone growing, and
External have minimizing osteoclast number, weakens osteoclast absorption function.
Rhizoma Drynariae extract of the present invention refers to the extract that Rhizoma Drynariae dry rhizome obtains through alcohol extraction, and tool the kidney invigorating is strong
Bone, continuous hinder pain relieving, the effect of continuous wound of invigorating blood circulation, for lumbago due to renal deficiency, Hiccough and deaf, odontoseisis, fall wink frustrate, injured bone.
There is promotion external osteoblastic proliferation, differentiation, the effect of suppression TNF-a Induced Apoptosis in Osteoblasts simultaneously, i.e. there is osteoporosis and live
Property.
Mushroom powder of the present invention, rich in natural complex D, is that fresh white mushroom is exposed to doses, special wavelength
Low-energy ultraviolet (UVB) under, in this environment, the vitamin D2 precursors ergosterol portion contained in a large number in mushroom
Divide and be converted into vitamin D2 (ergocalciferol), thus obtain rich in natural complex D mushroom powder.And the irradiation of this dosage,
The overall structure of mushroom will not be had any impact, nor structure and the content of its nutritional labeling can be changed.Natural dimension
Raw element D is a kind of fatsoluble vitamin, is counted as a kind of hormone precursor acting on Ca,P metabolism, can promote the suction of calcium phosphorus
Receive, can mobilize out from bone by calcium phosphorus again, make plasma calcium, phosphorus reach normal value, promote mineralizing of bone, and constantly update,
The balance of two-ways regulation calcium updates, and makes skeleton dynamic.
Preferably, in described mushroom powder, vitamin D2 content is 100 μ g/g.
Magnesium carbonate in compositions of the present invention mainly provides magnesium elements.Human body has the magnesium of 55% to be present in skeleton,
Magnesium is also bone crystals inalienable part, limits the absorption of magnesium, can increase the mobilization of calcium, reduces the formation of sclerotin.Magnesium
Supplement and can play the formation of complementary effect, beneficially sclerotin with supplementary calcium.
Phosphopeptide caseinate is with bovine casein as raw material, hydrolyzes through single enzyme or compound enzyme system, more separated, purification
And the one obtained contains phosphoserine bunch, molecular weight is the natural physiological active peptide of 2000-4000.Phosphopeptide caseinate is
A kind of good Analyses of High Affinity Binding Peptides, in animal small intestine condition can with divalent minerals ions binding such as calcium, ferrum, magnesium, zinc, selenium,
Prevent calcium phosphate precipitation, strengthen the concentration of enteral dissolvable mine material, thus promote to absorb.Combination of the present invention
Phosphopeptide caseinate in thing can in small intestinal binding transport calcium, be equivalent to the short-distance transport protection instrument of calcium, it is to avoid calcium
Run off during circulation, promote absorption and the utilization of calcium.
Menaquinone K6 in compositions of the present invention has the effect treating and preventing osteoporosis, and vitamin
K2 generates bone protein, more jointly generates sclerotin with calcium, increases bone density, prevents fracture.
In some specific embodiments of the present invention, compositions of the present invention is made up of following raw material: de-
Fat milk powder 230 parts, oligofructose 200 parts, yak bone powder 180 parts, orangeade fruit powder 160 parts, D-Glucosamine Hydrochloride 120
Part, bone collagen 85 parts, chondroitin sulfate 80 parts, Herba Epimedii extract 20 parts, Rhizoma Drynariae extract 20 parts, mushroom powder 6 parts,
Magnesium carbonate 1.6 parts, phosphopeptide caseinate 0.9 part, Menaquinone K6 0.5 part.
In some specific embodiments of the present invention, compositions of the present invention is made up of following raw material: low
Polyfructose. 180 parts, yak bone powder 180 parts, orangeade fruit powder 160 parts, D-Glucosamine Hydrochloride 130 parts, bone collagen
90 parts, chondroitin sulfate 90 parts, Herba Epimedii extract 25 parts, Rhizoma Drynariae extract 25 parts, mushroom powder 6 parts, magnesium carbonate 1.2 parts,
Phosphopeptide caseinate 1 part, Menaquinone K6 0.4 part.
In other specific embodiments of the present invention, compositions of the present invention is made up of following raw material:
Oligofructose 20 parts, yak bone powder 100 parts, D-Glucosamine Hydrochloride 100 parts, bone collagen 50 parts, chondroitin sulfate
65 parts, Herba Epimedii extract 15 parts, Rhizoma Drynariae extract 15 parts, mushroom powder 9 parts, magnesium carbonate 1 part, phosphopeptide caseinate 1 part, dimension
Raw element K2 0.8 part.
Skimmed milk powder in heretofore described compositions, oligofructose, Os Bovis grunniens, orangeade fruit powder, D-aminoglucose
Sugar hydrochlorate, bone collagen, chondroitin sulfate, Herba Epimedii extract, Rhizoma Drynariae extract, mushroom powder, magnesium carbonate, casein
Phosphoeptide, Menaquinone K6 are to well known to a person skilled in the art, can be commercially available by commercial sources or pass through prior art
Disclosed in method prepare, its specification meets country or industry standard.
Present invention also offers the preparation method of described compositions, by Herba Epimedii extract, Rhizoma Drynariae extract pulverize with
Skimmed milk powder, oligofructose, yak bone powder, orangeade fruit powder, D-Glucosamine Hydrochloride, bone collagen, chondroitin sulfate
Element, mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6 are put by the method that equivalent is progressively increased and are mixed in blender and get final product.
Wherein, 100 mesh sieves are crossed after described Herba Epimedii extract, Rhizoma Drynariae extract are preferably pulverized.
In a specific embodiment, per os of the present invention gavage once a day gives rat tested material once a day, even
Continuous gavage 3 months, weighs weekly and adjusts gavage amount by body weight.Experiment end femoral artery sacrificed by exsanguination animal, takes out right lateral thigh
Bone, in 105 DEG C of baking ovens, bakes to constant weight, claims bone measurement.This bone bone density is represented with the mean bone density of bone.Employing atom is inhaled
Receive spectrophotometry right femur calcium content.Result display test compositions of the present invention basic, normal, high dosage group and low calcium
Matched group, in body weight, tests front no significant difference, after experiment, body weight variant (P < 0.05), right bone bone weight；Of the present invention
Compositions basic, normal, high dosage group, high dose calcium carbonate group compare with low calcium matched group and have significant difference (P < 0.01), its
On calcium content of bone, compositions of the present invention middle and high dosage group, high dose calcium carbonate group compare with low calcium matched group have notable
Sex differernce (P < 0.01).Compositions of the present invention basic, normal, high dosage group compares midpoint bone density and far-end with low calcium matched group
Bone density has significant difference (P < 0.01).Show that calcium content of bone and bone density are all notable in height calcium matched group, there is increasing
Add the function of bone density.
Therefore the invention provides the application in preparation promotes the health food of skeletal system health of the described compositions.
Preferably, described promotion skeletal system health is for increasing bone density.
Compositions of the present invention can be prepared as the various conventional formulations of health food, example by this area conventional formulation method
As, can add acceptable additive in bromatology in the compositions of effective dose of the present invention, such as disintegrating agent, lubricant,
Adhesive, dispersant etc., with conventional formulation method, be prepared as various common dosage forms.The present invention be preferably made powder, granule,
Tablet or capsule.
To those skilled in the art, in the case of knowing active component, can be according to conventional formulation method, gently
Easy makes various formulation products, and the adjuvant employed in preparation is the most well known in the art simultaneously.
From above technical scheme, compositions of the present invention includes skimmed milk powder, oligofructose, Os Bovis grunniens, Fructus Citri tangerinae
Fruit powder, D-Glucosamine Hydrochloride, bone collagen, chondroitin sulfate, Herba Epimedii extract, Rhizoma Drynariae extract, mushroom
Mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6, to sufferers of osteoporosis face, and ankylosis, arthritis, hyperostosis
The crowd of the skeletal system obstacles such as life, arthralgia cramp has significant preventive and therapeutic effect, can increase bone density, play promotion bone
The effect of bone system health.Compositions of the present invention may be used for preparation and promotes the health food of skeletal system health, application
In extensive range, there is good economy and social effect.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the present invention rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under not making creative work premise, all
Belong to the scope of protection of the invention.
In order to be better understood from the present invention, below in conjunction with embodiment, the present invention is expanded on further.If no special instructions, originally
Invent other raw materials used and reagent in each component in the compositions provided and application thereof all to be buied by market.Such as skimmed milk
Powder is purchased from Nestle Shuangcheng Ltd；Oligofructose is purchased from Quantum Hi-Tech (China) Biological Co., Ltd.；Yak bone powder is purchased
From Qinghai Xue Niu biological engineering company limited；Orangeade fruit powder is purchased from TaiWan, China Quan Ya limited company；D-aminoglucose
Sugar hydrochlorate is purchased from neoplasm pharmaceutical Co. Ltd of Jiangsu Australia；Bone collagen is purchased from Dong Bao Biotechnology Ltd.；
Chondroitin sulfate is purchased from Jiaxing Heng Jie bio-pharmaceuticals limited company；Herba Epimedii extract has purchased from sky source, Fushun biotechnology
Limit company；Rhizoma Drynariae extract is purchased from Hao Yuan bio tech ltd, Fushun；Mushroom powder is purchased from Qingdao Miao Pin source international trade
Company limited's (imported from America)；Magnesium carbonate is purchased from Shanghai Li Cheng nutrition product Science and Technology Co., Ltd.；Phosphopeptide caseinate
(CPP) purchased from New Zealand's tower figure；Menaquinone K6 is purchased from Shuan Jun bio tech ltd, Guangdong.
Embodiment 1,
Formula:
Skimmed milk powder 230 weight portion, oligofructose 200 weight portion, yak bone powder 180 weight portion, orangeade fruit powder 160 weight
Amount part, D-Glucosamine Hydrochloride 120 weight portion, bone collagen 85 weight portion, chondroitin sulfate 80 weight portion, Herba Epimedii
Extract 20 weight portion, Rhizoma Drynariae extract 20 weight portion, mushroom powder (rich in natural complex D 100 μ g/g) 6 weight portions, carbon
Acid magnesium 1.6 weight portion, phosphopeptide caseinate 0.9 weight portion, Menaquinone K6 0.5 weight portion.
Preparation method:
(1) weigh Herba Epimedii extract respectively, Rhizoma Drynariae extract pulverized 100 mesh sieves；
(2) recipe quantity oligofructose, yak bone powder, orangeade fruit powder, D-Glucosamine Hydrochloride, ossein egg are taken
In vain, chondroitin sulfate, Herba Epimedii extract, Rhizoma Drynariae extract, mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6,
The method progressively increased by equivalent is put in blender and is mixed 30 minutes, to uniform color, puts in fluidised bed granulator and is dried, and moisture content is less than
5%, cross 30 mesh sieves, detect qualified after, be distributed into 10g/ bag by automatic packer.
Embodiment 2,
Formula:
Oligofructose 180 weight portion, yak bone powder 180 weight portion, orangeade fruit powder 160 weight portion, D-glucosamine
Hydrochlorate 130 weight portion, bone collagen 90 weight portion, chondroitin sulfate 90 weight portion, Herba Epimedii extract 25 weight portion, bone
Broken benefit extract 25 weight portion, mushroom powder (rich in natural complex D 100 μ g/g) 6 weight portions, magnesium carbonate 1.2 weight portion, cheese
Protein phosphatase polypeptide 1 weight portion, Menaquinone K6 0.4 weight portion.
Preparation method:
(1) weigh Herba Epimedii extract respectively, Rhizoma Drynariae extract pulverized 100 mesh sieves；
(2) recipe quantity oligofructose, yak bone powder, orangeade fruit powder, D-Glucosamine Hydrochloride, ossein egg are taken
In vain, chondroitin sulfate, Herba Epimedii extract, Rhizoma Drynariae extract, mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6,
The method progressively increased by equivalent is put in blender and is mixed 30 minutes, to uniform color, puts in fluidised bed granulator and is dried, water weight portion
Less than 5%, cross 30 mesh sieves, detect qualified after, be distributed into 8g/ bag by automatic packer.
Embodiment 3,
Formula:
Oligofructose 20 weight portion, yak bone powder 100 weight portion, D-Glucosamine Hydrochloride 100 weight portion, ossein
Albumen 50 weight portion, chondroitin sulfate 65 weight portion, Herba Epimedii extract 15 weight portion, Rhizoma Drynariae extract 15 weight portion, mushroom
Mushroom powder (rich in natural complex D 100 μ g/g) 9 weight portions, magnesium carbonate 1 weight portion, phosphopeptide caseinate 1 weight portion, vitamin
K2 0.8 weight portion.
Preparation method:
(1) weigh Herba Epimedii extract respectively, Rhizoma Drynariae extract pulverized 100 mesh sieves；
(2) recipe quantity oligofructose, yak bone powder, orangeade fruit powder, D-Glucosamine Hydrochloride, ossein egg are taken
In vain, chondroitin sulfate, Herba Epimedii extract, Rhizoma Drynariae extract, mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6,
The method progressively increased by equivalent is put in blender and is mixed 30 minutes, to uniform color, puts in fluidised bed granulator and is dried, water weight portion
Less than 5%, cross 30 mesh sieves, add proper auxiliary materials, put in Multidimensionblender mix 20 minutes, detect qualified after, tabletting.
Embodiment 4, effect experimental
1, sample prepared by formula described in test specimen embodiment 1 and technique.It is 2.4g/60kg that people recommends dosage
BW day.
2, laboratory animal: select the ablactation SD male rat of about 28 days, body weight 60-85 gram.Experimental situation is temperature 20
DEG C-25 DEG C, relative humidity 40%-60%.
3, dosage choice: experiment sets low calcium matched group (150mg/100g feedstuff) and calcium carbonate control group (1200mg/kg
And test specimen basic, normal, high (200mg/kg BW, 600mg/kg BW, 1200mg/kg BW) three dosage groups, often groups BW)
12 rats.
4, experimental technique
Each group all feeds low calcium normal feedstuff, drinking pure water.Per os gavage once a day gives rat tested material.Rat fills
(preparation of gavage liquid: sample 2g, 6g, 12g of Example 1 preparation respectively, adds distilled water and is settled to 100m1, be configured to gastric juice
200mg/kb bw, 600mg/kb bw, the gavage liquid of 1200mg/kb bw group)；High dose calcium carbonate control group per os pours into
The calcium carbonate of 334mg/kb bw, this dosage is equivalent to test specimen high dose group calcium level, and (test specimen calcium content is 40g carbon
Acid calcium/100g sample, in high dose group 1200mg/kb bw, calcic is 200.4mg/kb bw, is converted into calcium carbonate:
501mg/kb·bw.The preparation of gavage liquid: take calcium carbonate 5g and add distilled water and be settled to 100mL).
All animal gavage amounts are 10mg/kb bw, once a day, continuous gavage 3 months, weigh weekly and by body
Recanalization gavage amount.Experiment end femoral artery sacrificed by exsanguination animal, takes out left femur and right side femur, respectively in 105 DEG C of baking ovens
In, bake to constant weight, claim bone measurement.DXP-L Dual-energy X-rays absorptionmetry is used to scan whole fl, with the mean bone density of bone
Represent this bone bone density.Use atomic absorption spectroscopy determination right femur calcium content.
Table 1 compositions is on body weight, right femur weight and the impact of calcium content of bone
As can be seen from Table 1, test specimen basic, normal, high dosage group and low calcium matched group are in body weight, without substantially before experiment
Difference, after experiment, body weight variant (P < 0.05)；And right bone bone weight, test specimen basic, normal, high dosage group, high dose calcium carbonate
Organize to compare with low calcium matched group and there is significant difference (P < 0.01), on its calcium content of bone, test specimen middle and high dosage group, height
Dosage calcium carbonate group compares with low calcium matched group and has significant difference (P < 0.01).
The impact on rat bone density of table 2 compositions
| Group | Midpoint bone density | Distal bone density |
| Low calcium matched group | 0.08±0.01 | 0.05±0.02 |
| High dose calcium carbonate group | 0.2±0.01 | 0.25±0.02 |
| Test specimen low dose group | 0.12±0.02** | 0.18±0.01** |
| Dosage group in test specimen | 0.15±0.02** | 0.22±0.02** |
| Test specimen high dose group | 0.19±0.03** | 0.24±0.02** |
As can be seen from Table 2, test specimen basic, normal, high dosage group compares midpoint bone density and far-end with low calcium matched group
Bone density has significant difference (P < 0.01).
The compositions of Example 2 and embodiment 3 preparation carries out above-mentioned experiment, the group that experimental result is prepared with embodiment 1
Compound effect is same or like, without significant difference (P ＞ 0.05).
Compositions calcium content of bone the most of the present invention and bone density are all notable in height calcium matched group, show this
Bright described compositions has the function increasing bone density.
Claims (10)
1. a compositions, is made up of following raw material:
Skimmed milk powder 0-230 part, oligofructose 0-200 part, yak bone powder 50-190 part, orangeade fruit powder 0-170 part, D-amino
Glucosamine salt hydrochlorate 100-140 part, bone collagen 0-100 part, chondroitin sulfate 65-95 part, Herba Epimedii extract 15-25
Part, Rhizoma Drynariae extract 15-25 part, mushroom powder 4-9 part, magnesium carbonate 0.1-2.1 part, phosphopeptide caseinate 0.1-1.3 part, dimension life
Element K2 0.1-0.9 part.
Compositions the most according to claim 1, it is characterised in that be made up of following raw material: skimmed milk powder 230 parts,
Oligofructose 200 parts, yak bone powder 180 parts, orangeade fruit powder 160 parts, D-Glucosamine Hydrochloride 120 parts, ossein egg
White 85 parts, chondroitin sulfate 80 parts, Herba Epimedii extract 20 parts, Rhizoma Drynariae extract 20 parts, mushroom powder 6 parts, magnesium carbonate 1.6
Part, phosphopeptide caseinate 0.9 part, Menaquinone K6 0.5 part.
Compositions the most according to claim 1, it is characterised in that be made up of following raw material: oligofructose 180 parts,
Yak bone powder 180 parts, orangeade fruit powder 160 parts, D-Glucosamine Hydrochloride 130 parts, bone collagen 90 parts, chondroitin sulfate
Element 90 parts, Herba Epimedii extract 25 parts, Rhizoma Drynariae extract 25 parts, mushroom powder 6 parts, magnesium carbonate 1.2 parts, phosphopeptide caseinate 1
Part, Menaquinone K6 0.4 part.
Compositions the most according to claim 1, it is characterised in that be made up of following raw material: oligofructose 20 parts, yak
Os Bovis seu Bubali powder 100 parts, D-Glucosamine Hydrochloride 100 parts, bone collagen 50 parts, chondroitin sulfate 65 parts, Herba Epimedii extract
Thing 15 parts, Rhizoma Drynariae extract 15 parts, mushroom powder 9 parts, magnesium carbonate 1 part, phosphopeptide caseinate 1 part, Menaquinone K6 0.8 part.
5. according to compositions described in claim 1-4 any one, it is characterised in that in described mushroom powder, vitamin D2 content is
100μg/g。
6. preparation method of composition described in claim 1-5 any one, it is characterised in that by Herba Epimedii extract, Rhizoma Drynariae
Extract is pulverized and skimmed milk powder, oligofructose, yak bone powder, orangeade fruit powder, D-Glucosamine Hydrochloride, ossein egg
In vain, chondroitin sulfate, mushroom powder, magnesium carbonate, phosphopeptide caseinate, Menaquinone K6 are put in blender mixed by the method that equivalent is progressively increased
Close and get final product.
7. the application in preparation promotes the health food of skeletal system health of the compositions described in claim 1-5 any one.
Apply the most according to claim 7, it is characterised in that described promotion skeletal system health is for increasing bone density.
9. a health food, it is characterised in that include compositions and food described in the claim 1-5 any one of effective dose
Acceptable additive on.
Health food the most according to claim 9, it is characterised in that it is powder, granule, tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610613602.3A CN106235311A (en) | 2016-07-28 | 2016-07-28 | A kind of compositions promoting skeletal system health and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610613602.3A CN106235311A (en) | 2016-07-28 | 2016-07-28 | A kind of compositions promoting skeletal system health and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106235311A true CN106235311A (en) | 2016-12-21 |
Family
ID=57606726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610613602.3A Pending CN106235311A (en) | 2016-07-28 | 2016-07-28 | A kind of compositions promoting skeletal system health and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106235311A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106578094A (en) * | 2016-12-31 | 2017-04-26 | 东北农业大学 | Old-aged formula milk powder for preventing osteoporosis |
| CN109007821A (en) * | 2018-08-07 | 2018-12-18 | 青岛明月海藻生物科技有限公司 | A kind of gel jelly and preparation method thereof improving articulation health |
| CN109793168A (en) * | 2019-02-20 | 2019-05-24 | 吉林大学 | A kind of ginseng ox bone marrow bone meal chewable tablets and preparation method thereof with Psoralen calcium-enriching function |
| CN110115385A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of strength osteocomma increasing bone density and its production method |
| CN110292177A (en) * | 2019-07-24 | 2019-10-01 | 武汉正轩宇生物科技有限公司 | A kind of composition and its preparation method and application promoting children's bone growth and development |
| CN110338409A (en) * | 2019-08-02 | 2019-10-18 | 武汉正轩宇生物科技有限公司 | It is a kind of to prevent and treat the composition and its application that women's bone amount is lost |
| CN110897152A (en) * | 2019-11-22 | 2020-03-24 | 安徽萨普丽生物医药有限公司 | Composition and capsule for increasing bone mineral density and preparation method thereof |
| CN111418664A (en) * | 2020-04-20 | 2020-07-17 | 石家庄君乐宝乳业有限公司 | Modified milk powder for promoting bone growth and protecting eyesight and preparation method thereof |
| CN111616232A (en) * | 2020-06-12 | 2020-09-04 | 北安宜品努卡乳业有限公司 | Children milk powder for promoting bone growth and preparation method thereof |
| CN112089040A (en) * | 2019-06-18 | 2020-12-18 | 湖南吉美生物科技发展有限公司 | Bovine bone meal prebiotics compound seasoning and preparation method and application thereof |
| CN112316105A (en) * | 2020-11-17 | 2021-02-05 | 琛蓝(美国)营养制品股份有限公司 | Compound composition with function of promoting bone health and preparation method and application thereof |
| CN113115953A (en) * | 2019-12-31 | 2021-07-16 | 北京司晨扬帆国际管理咨询有限公司 | Health food for increasing bone mineral density and preparation method thereof |
| CN115399473A (en) * | 2021-05-27 | 2022-11-29 | 深圳市回春堂健康管理服务有限公司 | Yak marrow high-calcium protein powder composition for increasing bone density and preparation method thereof |
| CN116196319A (en) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | Use of oligosaccharides for protecting cartilage |
| CN116369532A (en) * | 2023-05-16 | 2023-07-04 | 洛阳维尔健生物工程有限公司 | Solid preparation for promoting bone health and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885304A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | BMD (bone mineral density)-increased health food composite and preparation method thereof |
| CN104206949A (en) * | 2014-08-04 | 2014-12-17 | 江苏康缘阳光药业有限公司 | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product |
-
2016
- 2016-07-28 CN CN201610613602.3A patent/CN106235311A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885304A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | BMD (bone mineral density)-increased health food composite and preparation method thereof |
| CN104206949A (en) * | 2014-08-04 | 2014-12-17 | 江苏康缘阳光药业有限公司 | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product |
Non-Patent Citations (1)
| Title |
|---|
| 吴益群等: "各类营养物质与骨骼健康", 《中国骨质疏松杂志》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106578094A (en) * | 2016-12-31 | 2017-04-26 | 东北农业大学 | Old-aged formula milk powder for preventing osteoporosis |
| CN110115385A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of strength osteocomma increasing bone density and its production method |
| CN109007821A (en) * | 2018-08-07 | 2018-12-18 | 青岛明月海藻生物科技有限公司 | A kind of gel jelly and preparation method thereof improving articulation health |
| CN109793168A (en) * | 2019-02-20 | 2019-05-24 | 吉林大学 | A kind of ginseng ox bone marrow bone meal chewable tablets and preparation method thereof with Psoralen calcium-enriching function |
| CN112089040A (en) * | 2019-06-18 | 2020-12-18 | 湖南吉美生物科技发展有限公司 | Bovine bone meal prebiotics compound seasoning and preparation method and application thereof |
| CN110292177A (en) * | 2019-07-24 | 2019-10-01 | 武汉正轩宇生物科技有限公司 | A kind of composition and its preparation method and application promoting children's bone growth and development |
| CN110338409A (en) * | 2019-08-02 | 2019-10-18 | 武汉正轩宇生物科技有限公司 | It is a kind of to prevent and treat the composition and its application that women's bone amount is lost |
| CN110897152A (en) * | 2019-11-22 | 2020-03-24 | 安徽萨普丽生物医药有限公司 | Composition and capsule for increasing bone mineral density and preparation method thereof |
| CN113115953A (en) * | 2019-12-31 | 2021-07-16 | 北京司晨扬帆国际管理咨询有限公司 | Health food for increasing bone mineral density and preparation method thereof |
| CN111418664A (en) * | 2020-04-20 | 2020-07-17 | 石家庄君乐宝乳业有限公司 | Modified milk powder for promoting bone growth and protecting eyesight and preparation method thereof |
| CN111616232A (en) * | 2020-06-12 | 2020-09-04 | 北安宜品努卡乳业有限公司 | Children milk powder for promoting bone growth and preparation method thereof |
| CN112316105A (en) * | 2020-11-17 | 2021-02-05 | 琛蓝(美国)营养制品股份有限公司 | Compound composition with function of promoting bone health and preparation method and application thereof |
| CN115399473A (en) * | 2021-05-27 | 2022-11-29 | 深圳市回春堂健康管理服务有限公司 | Yak marrow high-calcium protein powder composition for increasing bone density and preparation method thereof |
| CN116196319A (en) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | Use of oligosaccharides for protecting cartilage |
| CN116196319B (en) * | 2021-11-30 | 2024-06-04 | 内蒙古伊利实业集团股份有限公司 | Use of oligosaccharides for protecting cartilage |
| CN116369532A (en) * | 2023-05-16 | 2023-07-04 | 洛阳维尔健生物工程有限公司 | Solid preparation for promoting bone health and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| CN102940151B (en) | Feed for improving egg laying performance of laying duck | |
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN103083650B (en) | Composition with bone mineral density addition function, and preparation method as well as application of composition | |
| CN102423487B (en) | Osteoarticular health-care composition and its application | |
| CN101773539B (en) | Prescription with function for mitigating and curing osteoarthrosis | |
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN105056216A (en) | Calcium supplementing preparation/granule and preparation method thereof | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN103736074A (en) | Bone mineral density increase health capsule and preparation method thereof | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| CN110090279A (en) | It is a kind of prevent and treat fowl gout Chinese medicine composition and its preparation, application method | |
| CN105079028A (en) | Health care product capable of improving bones and joints and preparation method of health care product | |
| CN103656626B (en) | Compound complexing calcium preparation for treating and nourishing bones for middle and old aged people and preparation method thereof | |
| CN104824677A (en) | Bone density increase health food and preparation method thereof | |
| CN109892555A (en) | A kind of diet food and preparation method thereof for hindering Fatty synthesis to accelerate oil extraction fat reducing | |
| CN101455396A (en) | Nutrient health-care food capable of promoting bone and bone arthrosis health | |
| WO2016043668A1 (en) | A composition suitable for vegetarians providing calcium supplementation as well as gout prevention and treatment and the method of preparation thereof | |
| CN103156889A (en) | Capsule for enhancing bone mineral density, and preparation method thereof | |
| CN105595327A (en) | Special calcium citrate preparation for astronauts | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| CN108968075A (en) | It is a kind of improve bone health composition and its application | |
| CN103238839A (en) | Food composition containing collagen used for maintaining joints | |
| CN105831738A (en) | Polypeptide glucosamine chondroitin nutritional health food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170209 Address after: 510900 Guangdong City, Conghua District, suburban street, No., cross river road, No. -29 (A plant) on the first floor Applicant after: Guangzhou Kang Qilai Biotechnology Co. Ltd. Address before: 510000 Guangdong City, Guangzhou Province, Guangzhou International Biological Island spiral No. four on the 1st floor of the production area, unit fifth, unit 502, Applicant before: GUANGZHOU SALIAI STEMCELL SCIENCE AND TECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161221 |
|
| RJ01 | Rejection of invention patent application after publication |